This document provides an overview of bladder cancer, including its subtypes, risk factors, molecular landscape, management approaches, and outcomes. Key points include:
- Bladder cancer is categorized into non-muscle invasive (75%) and muscle invasive (25%) subtypes with different prognoses.
- Risk factors include smoking, chemical exposures, and infections. Molecular subtypes include luminal, basal, and neuroendocrine types.
- Treatment depends on invasiveness and risk level. Non-muscle invasive types often receive transurethral resection and adjuvant BCG therapy. Muscle invasive types may undergo radical cystectomy or trimodality therapy with chemotherapy and radiation.
- Prognosis depends
Bladder cancer is a disease of urinary bladder in which cells grow abnormally and have the potential to spread to other parts of the body. This is one of four parts of presentations on Bladder cancer. Please do go through the rest of the presentations too.
Bladder cancer is a disease of urinary bladder in which cells grow abnormally and have the potential to spread to other parts of the body. This is one of four parts of presentations on Bladder cancer. Please do go through the rest of the presentations too.
Target audience : Oncology fellows and Oncologists.
Four challenging cases of Bladder cancer and managing decisions including latest management principles are discussed here.
Cancer that forms in tissues of the bladder (the organ that stores urine). Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the bladder). Other types include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). The cells that form squamous cell carcinoma and adenocarcinoma develop in the inner lining of the bladder as a result of chronic irritation and inflammation.
Urinary bladder collects urine from the kidney which is then passed through the urethra. Cancer is abnormal growth of cells leading to tumour in urinary bladder. Bladder Cancer is diagnosed with cystoscopy and biopsy . Treatment of Bladder cancer is done as per stage. It includes Radical Cystectomy, Plevic Lymphadenectomy, Ileal conduit, Neobladder as surgical options.
Carcinoma rectum the complete aproach to how to investigate and treat a case ...nikhilameerchetty
this is a complete guide to the understanding of the anatomy clinical features and the latest investigation to the most modern methods of treating the case of carcinoma rectum , all the latest journal published and the ongoing trials hav been searched and incorporated
Target audience : Oncology fellows and Oncologists.
Four challenging cases of Bladder cancer and managing decisions including latest management principles are discussed here.
Cancer that forms in tissues of the bladder (the organ that stores urine). Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the bladder). Other types include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). The cells that form squamous cell carcinoma and adenocarcinoma develop in the inner lining of the bladder as a result of chronic irritation and inflammation.
Urinary bladder collects urine from the kidney which is then passed through the urethra. Cancer is abnormal growth of cells leading to tumour in urinary bladder. Bladder Cancer is diagnosed with cystoscopy and biopsy . Treatment of Bladder cancer is done as per stage. It includes Radical Cystectomy, Plevic Lymphadenectomy, Ileal conduit, Neobladder as surgical options.
Carcinoma rectum the complete aproach to how to investigate and treat a case ...nikhilameerchetty
this is a complete guide to the understanding of the anatomy clinical features and the latest investigation to the most modern methods of treating the case of carcinoma rectum , all the latest journal published and the ongoing trials hav been searched and incorporated
urinary bladder malignancy
incidence
risk factors and pathogenesis
staging of the disease
histopathology
transitional and non transitional cell carcinomas
clinical features
laboratory findings
imaging
molecular markers
treatment options
chemotherapy
radiotherapy
surgery
Urinary Bladder Cancer is diagnosed with cystoscopy and biopsy. Treatment is done as per the type of cancer and its stage. If the cancer is of first stage and / or low grade it is managed with surgery and intra vesical therapy. Surgery includes Trans Urethral Resection of Bladder Tumour. Intravesical therapy includes BCG, Mitomycin C and Gemcitabine. HIVEC is a latest technology in which Heated chemotherapy is circulated in Urinary Bladder .
Tumors of kidney and Bladder by Sunil Kumar Dahasunil kumar daha
Please find the power point on Tumors of kidney and Bladder. I tried present it on understandable way and all the contents are reviewed by experts and from very reliable references. Thank you
Non-Muscle Invasive Carcinoma Bladder Management Protocol.
CT (chest, pelvis)/MRI for muscle invasive disease only
Before TURBT if MI suspected
CT/MRI overstaged local tumor
80% accurate for local staging
80% accuracy for LN disease (>1cm)
PET no additional value
This is a general overview of options available to patients with liver dominant metastatic disease as well other focal areas of disease which may benefit from services provided by an interventional radiologist
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Bladder cancer
1. Bladder Cancer
Dr Ali Azher, MD (Radiation Oncology)
The Gujarat Cancer & Research Institute, BJ Medical College,
Ahmedabad, Gujarat
aliazhermuhammed@gmail.com
2. Introduction
• Three major categories
• Non muscle invasive bladder cancer (NMIBC) 75%
• Not penetrated epithelial basement membrane
• Ta to T1
• Muscle invasive bladder cancer (MIBC) 25%
• T2 or higher
• Poor prognosis
• Metastatic cancers
3. Quick review
• Risk factors- smoking, aromatic amines, nitrites/nitrates,
Cytoxan exposure, aniline dyes, Schistosoma haematobium
infection, chronic indwelling catheter (e.g. in patients with
spinal cord injury)
• Transitional Cell Carcinoma –93%
• Squamous Cell Carcinoma 5%
• Most common sites of the tumor are trigone, lateral and
posterior walls, an bladder neck
• Presentation: hematuria, irritative voiding, pelvic pain,
obstructive uropathy, hydronephrosis
• Lymphatic Drainage: hypogastric, obturator, internal and
external iliac, perivesical, sacral, presacral
4. Mutational Landscape
• FGFR 3
• ≥ 70% of Ta
• 10-45% T1 NMIBC
• 15% MIBC
• PI3K
• Low grade Ta 40-50%
• T1 NMIBC & MIBC 20%
• TERT
• Most common genomic alteration
• 60-80% all stages all grades
• Tumor suppressor genes
• TP53, RB1 and CDKN2A
• MIBC
5. • P53 most commonly mutated in MIBC 50%
• Very infrequent in low grade Ta – 1%
• Higher frequency in T1 – 35%
• Small association between P53 positivity & poor prognosis
• Both loss of expression & high level expression of P16 → RB
pathway down regulation
• Adverse prognostic biomarker
• Found in > 50% of MIBC
6. Molecular subtypes
• Similar to Breast Cancer
• Express markers of urothelial differentiation & normal basal
cells of urothelium (luminal & basal)
• Basal tumors – high levels of KRT5, KRT6, KRT14 & CD44
• Luminal – FGFR3, uroplakins
9. Field cancer & Multiclonality
• Monoclonality
• Transformed cell gives rise to daughter cells
• Exhibit same genetic changes
• Field cancer
• Urothelium is exposed to same urinary carcinogens →
transformation of many independent urothelial cells
• Multiple tumors, independent multiple sites
12. Jewett-Marshall
Staging(Clinical)
• Stage A: Submucosal invasion but no muscle invasion
• Stage B Bladder wall or muscle invasion
• B1 Superficial
• B2 Deep
• Stage C Extension through serosa into perivesical fat
• Stage D Lymph nodes and other distant metastasis
• D1 regional nodes
• D2 distant nodes and other distant mets
• AJCC T1 TO T4 = JEWETT A TO D
• N AND M PART OF STAGE D
13.
14. NMIBC
• 80% not involve muscularis propria
• Tis, Ta & T1
• 15-20% progress to T2 or greater
• < 5% NMIBC – Mets
• TURBT – Gold Standard
G/T Recurrence rate Progression rate
G1/G2/Ta 50% 5%
G3/T1/CIS/Multifocal 70% 30-50%
15. Number of tumors
Tumor size
Prior recurrence rate
Presence of CIS
T stage
Tumor grade
TURBT specimen
Risk stratification
16. AUA risk stratification
Risk group Features
Low risk Solitary low grade tumors ≤ 3cm
Ta G1
Intermediate Solitary low grade tumors >3cm
Solitary high gradeTa G2 G3
Multi focal low grade
Low grade recurrence within 1 year
Low grade T1
High risk High grade T1
Recurrent high grade Ta
High grade Ta>3cm
Multifocal
Any CIS
LVI
High grade prostatic urethral involvement
Any variant histology
BCG failure
17.
18. Risk group Recurrence rate % Progression risk %
Low risk
<3cm, Ta, G1, No CIS
15 0.2
Intermediate 38 5
High risk 61 17
20. Adjuvant Intravesical Drug
Therapy
• Lessen the rate of recurrence
• Following TURBT
• Multifocal CIS
• CIS + Ta or T1
• Any grade 3
• Multifocal tumors
• Rapidly recurring after TURBT
21. Drugs
• BCG
• Live attenuated form of mycobacterium bovis
• Triggers an immune response cascade
• Direct tumor cell suppression
• thioTEPA
• Mitomycin-C
• Doxorubicin
• Gemcitabine
22. Schedule
• Once a week for 6 weeks
• Followed by subsequent 3 weeks as induction
• No cystoscopic evidence of recurrence
• Ongoing maintenance BCG 6 week courses every 3-6 months
• Regular cystoscopic suveillance
• 32% reduction in risk of recurrence
• Optimal timing within 6hrs of TURBT
24. BCG failure
• BCG unresponsive
• Recurrence within 6 months
• BCG refractory
• HG non-muscle-invasive papillary tumor is present at 3 month
• CIS is present at both 3 and 6 months
• HG tumor appears during BCG therapy
• Intolerant
• Severe side effects
• Relapsing
• Recurrence of HG/grade 3 tumor after completion of BCG
maintenance, despite an initial response (1-2years)
BCG+IFNα or GEM or Docetaxel
26. MIBC
• 20-40%
• 85% of patients will die within 2 years if untreated
• Two school of thoughts
• US model
• UK model
27. Surgery
• Radical cystectomy
• Good long term survival rates
• Lowest local recurrences
• Accurate pathological staging & nodal status
• Timing – delay > 3 months after TURBT undermines patient
survival
• PLND
• Urinary diversions
28. Radical cystectomy
• En bloc removal of pelvic organs anterior to rectum
• Men – bladder, urachus, prostate, seminal vesicles & visceral
peritoneum
• Women - bladder, urachus, ovaries, fallopian tubes, uterus,
cervix, vaginal cuff & anterior pelvic peritoneum
• Lymphadenectomy
• Extended lymphadenectomy is beneficial
• Bilaterally all obsturator, hypogastric, presciatic & presacral LN
• >15 LNs sufficient
30. Survival after RC
P Stage Disease Specific Survival
%
OS %
pTa, Tis, T1 82
pT2, pN0
Organ cofined
73 49
pT3-pT4a or pN1-pN2
Non Organ cofined
33 23
LN positive 28 21
32. Recurrence following RC
• Pelvic
• Within the soft tissue field of exenteration
• 6-9%
• Distant
• Outside the pelvis
• 20-35%
• Urethral recurrence
• New primary tumor occurring in the retained urethra
33. North America model
• Trimodality therapy
• Maximal TURBT
• Chemotherapy
• Radiotherapy
• Split course RT
• 40Gy with synchronous CT → interval cystoscopy → total dose of
64-68Gy
• Selective bladder preservation
• Exit to surgery
37. • Bladder preservation is reserved for those with cCR to CRT
• Predictors of successful outcome
• Solitary T2 or T3
• < 6cm
• No hydronephrosis
• Visibly complete TURBT
• No Extensive CIS
• UC histology
38. UK model
• RT single course
• Radical RT after TURBT
• 64Gy in 32# → cystoscopy
• Younger/more fit – surgery
• Older/less fit – RT
Higher rate of bladder preservation
full dose radical RT + synchronous chemotherapy
43. Simulation
• Give oral contrast 1 hr before
• Ask patient to voiding urine
• Foley’s catheter inserted immediately after voiding urine
• 7CC Hypaque solution to inflate balloon and pull down at
base of bladder
• This volume is replaced by an equal volume of hypaque
solution plus an additional 25 ml and 10-15 ml of air then
clamp the catheter.
• Hypaque solution- Urographin :NS = 1: 3
• Air will rise to the top & define the anterior extension of
bladder.
44. • Simulator couch & positioned.
• pelvis is straight, relative to the axes of treatment couch.
• Following simulation & radiographic exposure of anterior
fields, rectal contrast may be given & lateral simulation is
exposed.
45. • Empty bladder :
• More reproducible
• More comfortable to patient
• Keep the Overall irradiated volume as small as possible.
• Minimize the risk of geographical miss
• Full bladder:
• Displaces small intestine & some part of rectum out of radiation
portals
46. • Phase I:
• The whole pelvis, encompassing the pelvic lymph nodes,
bladder, and proximal urethra
• Elective irradiation of the pelvic lymph nodes
47. 2D portals
• AP-PA
• Superior :at the L5-S1 disc space
• Inferior : below obturator foramen.
• Laterally:1.5-2 cm to the bony pelvis at its widest section
48. • Lateral field
• Superior & Inferior border same as in AP-PA portal
• Anterior : anterior to bladder with a margin with 1.5 – 2cm
• Posterior : 2-3 cm posterior to bladder
49. Phase II Boost
• PORTALS :
• Anterior –Bladder with a margin of 1-1.5cm
• Lateral – Bladder with a margin of 1-1.5cm
• Oblique– Selected at an angle which spares the rectum
completely and encompasses the bladder with 1.5 cm margin
• FIELDS : 3 fields
• 2 laterals and one anterior
• 2 obliques and one anterior
50. 3D – RT planning
• PLANNING CT
• Supine, arms on chest
• Knee and Ankle immobilization
• Empty Rectum (flatus & feces) – daily microenema
• Empty Bladder 15 minutes before
• Scan is performed with 3 mm slices from the bottom of L5
(above the dome of the bladder) to the bottom of the ischial
tuberosities.
• Radio opaque markers
55. Target volumes
• GTV = macroscopic tumor visible on CT/MRI/cystoscopy
• CTV Tumour –Whole bladder and any extra-vesical extension
• Men : entire prostate & Seminal Vesicles
• Women : Proximal 2 cm of urethra is also considered as part of
the target field
• CTV Nodal
• CTV Total = CTV Tumour+ CTV Nodal
• PTV 1= 1.5-2cm around CTV
• PTV Boost= CTV Tumour+ 1cm
62. Late toxicity
• Chronic irritative cystitis
• Hemorrhagic cystitis
• Bladder contracture
• Rectal stricture
• Small bowel obstruction
63. IGRT – rationale
• Organ motion
• Delineation errors
• Set up errors
• Treatment verification
• Reproducibility of bladder volume
64. Goals
• Accurate dose delivery to targeted areas
• Avoidance of normal structures by reducing the margins
around the CTV.
• Patient-specific variations assessed at treatment console with
volumetric 3D imaging modalities fitted to treatment
machines, such as kilovoltage CBCT.
65. Preoperative RT
• Waned
• Chemosensitivity of bladder cancer
• Subsequent improvements in radiation & surgical techniques
• Old, non randomised comparisons
• 40Gy
66. Postoperative RT
• Based on the grounds of positive margins & tumor spillage
• Anticipation of recurrences
68. Proton
• MIBC
• Proton boost
• 36.3Gy/11#
Late toxicities
Urinary hemorrage
Urethral stricture
Ureter stricture
OS Local control Bladder preservation
71.4 83.4 86.3
Recurrence 25%
69. Brachytherapy
• Indications
• Solitary T1 T2, 5mm or less diameter
• Contra indications
• Tumor invasion of bladder neck
• T3
• Multifocal
• LN (+)
• TURBT → EBRT 40Gy (Bladder+LN) → HDR BT within 1 week
• 2.5 Gy x 10#, 3# per day
• Conservation of bladder function
70. NACT
• To down size & down stage the tumors
• Occult micro mets in muscularis propria
• Standard of care in T3/T4 or node positive disease
• MVAC
• CMV
• dd MVAC (dense dose)
• Accelerated MVAC/high dose MVAC
• Compressed schedule over 14 days
• NCCN 2018
• Category 1 recommendation
• T2 – T4a
• dd MVAC
• CMV
• GC
71. Adjuvant CT
• More accurate selection of patients (p stage)
• Two settings
• Following bladder sparing chemoradiation
• Following radical cystectomy
• Regimens
• MCV
• GC
• Paclitaxel
• Standard recommendation
• Positive nodes
• High p Stage T3 T4
• LVI
72. Metastatic Bladder Cancer
• MVAC
• 28 day cycles
• Mtx 30mg/m2 Days 1, 15, 22
• Vinblastine 3mg/m2 Days 2, 15, 22
• Doxorubin 30mg/m2 Day 2
• Cisplatin 70mg/m2 Day 2
• CMV
• Omits Doxorubicin
• GC
• Gemcitabine 1000mg/m2 Days 1, 8, 15
• Cisplatin 70mg/m2 Day 2
• Less toxic, improved tolerability